Related Experiment Videos
Cost-benefit analysis of a new HEDIS performance measure for pneumococcal vaccination
Faruque Ahmed1, Elamin E Elbasha, Betsy L Thompson
1Division of Prevention Research and Analytic Methods, Epidemiology Program Office, Centers for Disease Control and Prevention, MS-K73, 4770 Buford Highway, Atlanta, GA 30341, USA. fahmed@cdc.gov
Objectives:
Measurement of the quality of care provided by managed care organizations (MCOs) has achieved national prominence, though there is controversy regarding its value. This article assesses the economic implications of a new Health Plan Employer Data and Information Set (HEDIS) measure for pneumococcal vaccination.
Methods:
A Markov decision model, with Monte Carlo simulations, was utilized to conduct a cost-benefit analysis of annual HEDIS-associated interventions, which were repeated for 5 consecutive years, in an average Medicare MCO, using a societal perspective and a 3% annual discount rate.
Results:
Compared with the status quo, the HEDIS intervention will be cost saving 99.8% of the time, with an average net savings of $3.80 per enrollee (95% probability interval: $0.73-$6.87).
Conclusions:
The new HEDIS measure will save societal dollars. This type of analysis is essential if performance measurement is to become a legitimate part of our health care landscape.